Adam Townsend - Aug 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Stock symbol
APLS
Transactions as of
Aug 8, 2022
Transactions value $
-$623,875
Form type
4
Date filed
8/9/2022, 05:22 PM
Previous filing
Aug 4, 2022
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $189K +12.5K +29.13% $15.09 55.4K Aug 8, 2022 Direct F1
transaction APLS Common Stock Sale -$813K -12.5K -22.56% $65.00 42.9K Aug 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12.5K -3.42% $0.00 353K Aug 8, 2022 Common Stock 12.5K $15.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale form an established 10b5-1 plan.
F2 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.